Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) executive chairman Dr Sotirios Stergiopoulos joined Proactive's Stephen Gunnion to discuss the appointment of Professor Ozgur Sahin as a Scientific Advisor to the company and the progress of lead cancer therapy AO-252.

Stergiopoulos explained why Sahin, a leading expert in TACC3 biology, is a key addition as the company advances the programme. He also highlighted encouraging early clinical data, including signs of tumour regression with no safety concerns reported to date, and outlined plans to begin dosing patients with a new AO-252 formulation in July.

For more interviews and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.

#CoiledTherapeutics #AO252 #PrecisionOncology #CancerResearch #Biotech #Oncology #ClinicalTrials #TACC3 #DrugDevelopment #HealthcareInnovation #CancerTreatment #MedicalResearch #Biotechnology #LifeSciences #ProactiveInvestors